References on website
1. Brembilla-Perrot B, Marçon O, Chometon F, Bertrand J, Terrier de la Chaise A, Louis P
et al. Supraventricular tachyarrhythmia as a cause of sudden cardiac arrest. J Interv Card
Electrophysiol. 2006;16:97-104.
2. Kafkas NV, Patsilinakos SP, Mertzanos GA et al. (2007). Conversion efficacy of
intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset
atrial fibrillation and atrial flutter. Int J Cardiol. 118, 321-325.
3. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide
compared with procainamide during human atrial flutter and fibrillation:
electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997;
96: 4298-306.
4. Neuss H, Schlepper M. Long-term efficacy and safety of flecainide for supraventricular
tachycardia. Am J Cardiol 1988; 62: 56D–61D.
5. Henthorn RW, Waldo AL, Anderson JL, et al., for the Flecainide Supraventricular
Tachycardia Study Group. Flecainide acetate prevents recurrence of symptomatic
paroxysmal supraventricular tachycardia. Circulation. 1991;83:119–125.
6. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in
the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6month double-blind comparison with propafenone and placebo. Am Heart J.
2001;142:93–98.
7. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic
paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover
trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539–544.
8. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainide therapy
in patients with atrioventricular re-entrant tachycardia. Ann Intern Med. 1991;114:189–
194.
9.Wiseman MN, Elstob JE, Camm AJ, et al. A study of the use of flecainide acetate in the
long-term management of cardiac arrhythmias. Pacing Clin Electrophysiol. 1990;13:767–
775.
10. Pritchett EL, DaTorre SD, Platt ML, et al., for the Flecainide Supraventricular
Tachycardia Study Group. Flecainide acetate treatment of paroxysmal supraventricular
tachycardia and paroxysmal atrial fibrillation: dose-response studies. J Am Coll Cardiol.
1991;17:297–303.
11. Kappenberger LJ, Fromer MA, Steinbrunn W, et al. Efficacy of amiodarone in the WolffParkinson-White syndrome with rapid ventricular response via accessory pathway during
atrial fibrillation. Am J Cardiol. 1984;54:330–335.
12,Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the WolffParkinson-White syndrome. Am Heart J 1983; 106:145-147.
13. Wellens HJ. Should catheter ablation be performed in asymptomatic patients with WolffParkinson-White syndrome? When to perform catheter ablation in asymptomatic patients
with a Wolff-Parkinson-White electrocardiogram. Circulation. 2005; 112: 2201-7;
discussion 2216.
14. Coumel P, Fidelle, J. Amiodarone in the treatment of cardiac arrhythmias in children: one
hundred thirty-five cases. Am Heart J 1980; 100: 1063–1069.
15. Natale A, Newby KH, Pisano E, Leonelli F, Fanelli R, Potenza D, Beheiry S, Tomassoni
G. Prospective randomized comparison of anti arrhythmic therapy versus first line
radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000; 35: 1898–
1904.
16. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM,
Hohnloser SH; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of
sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357: 987-99.